Pinworm drug, Mebendazole, targets cancers like GBM and osteosarcoma

Pinworm drug, Mebendazole, targets cancers like GBM and osteosarcoma

Researcher Gregory Riggins at Johns Hopkins Cancer Center in Baltimore has observed that an animal version of Mebendazole used to treat mice with pinworms, had quite an important side-effect. 





Pinworms are an increasing threat to Americans with over 40 million developing an infection every year. Mebendazole treats a number of parasitic worm infections.






What was special in these tests was that all the mice had been given brain tumour cells. But the mice taking the mebendazole equivalent didn’t develop any brain tumours!






So could Mebendazole be used to treat GBM, glioblastoma, the most deadly form of the disease?






Riggins has completed phase I clinical trials which primarily measure safety. And Mebendazole passed in humans – both children and adults.






All this is not actually new news. Back in 2002, Mebendazole showed an effect against lung cancer cells, causing dose-dependent apoptosis (cancer cell death). Then mice were given non-small cell lung cancer, and Mebendazole stopped the growth of the disease, with 80 per cent less metastases.






Work followed with adrenocortical cancer and melanoma, showing a similar pattern of results, as a thorough overview has shown(1).






By 2011, similar results were shown with osteosarcomas. Two clinical trials are currently underway with brain tumours.


















2017 Research
CancerAcitve Logo
Subscribe (Free e-Newsletter)

Join Our

Join Our Newsletter Signup today for free and be the first to get notified on new updates.